Clinical TrialsAcasunlimab and pembrolizumab combo shows encouraging efficacy in mNSCLC with a 12-month OS rate of 69% and a median OS of 17.5 months.
Oncology PortfolioPositive updates from BNT311, BNT326, and BNT327 reinforce confidence in an $11bn pipeline value.
Vaccine DevelopmentSince the Moderna and BioNTech vaccine approaches are the most rapidly updatable, BioNTech and Pfizer are expected to swiftly follow Moderna in submitting the JN.1 lineage-targeting version of their COVID-19 vaccine to the FDA for review.